Core Insights - Vericel (NASDAQ: VCEL) operates in the regenerative medicine sector, which is currently undervalued by the market [1] - The company has achieved steady revenue growth through FDA-approved products such as MACI, Epicel, and NexoBrid, contrasting with larger biotech firms focused on blockbuster drug approvals [1] Company Overview - Vericel has established a niche in regenerative medicine, differentiating itself from larger biotech companies [1] - The company’s revenue-generating products are recognized for their FDA approval, contributing to consistent revenue growth [1] Market Position - The market tends to overlook Vericel in favor of larger biotech names, despite its strong performance and growth potential [1] - The focus on high-growth companies in sectors with potential for exponential expansion aligns with Vericel's business model [1]

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences: TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025Canaccord Genuity 2025 Musculoskeletal Conference on Monday, March 10, 2025Leerink Partners 2025 Global Healthcare Conference on Wednesday, March 12, 2025 A webcast of the presentatio ...

Group 1 - Vericel Corporation held its Q4 2024 earnings conference call on February 27, 2025, at 8:30 AM ET [1][2] - The call featured key company executives including CEO Nick Colangelo and CFO Joe Mara [3] - The conference call was recorded and participants were initially in a listen-only mode [2][4] Group 2 - Forward-looking statements were made during the call, which are subject to risks and uncertainties that could lead to actual results differing from expectations [4] - The company provided access to its fourth quarter financial results press release and a presentation with highlights from the call on its Investor Relations website [4]

Vericel Corporation (NASDAQ:VCEL) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Nick Colangelo - CEO Joe Mara - CFO Eric Burns - VP, Finance and IR Conference Call Participants Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Felipe Lamar - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Genuity Mason Carrico - Stephens, Inc. Jeffrey Cohen - Ladenburg Thalmann & Co. Swayampakula Ramakanth - H.C. Wainwright & Co. Operator Good day, and thank you ...

Vericel Corporation (VCEL) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.67%. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.02, delivering a surprise of 60%.Over the last four quarters, the company has ...

VERICEL Q4 2024 RESULTS FEBRUARY 27, 2025 Safe Harbor Vericel cautions you that all statements other than statements of historical fact included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35280 VERICEL CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No ...

Exhibit 99.2 'VERICEL Advanced Therapies for the Sports Medicine & Severe Burn Care 43RD ANNUAL J.P. MO HEALTHCARE CONFER These and other significant factors are dis in Vericel's Annual Report on Form 10- December 31, 2023, filed with the Se Commission (SEC) on February 29, 202 Report on Form 10-Q for the quarter ende filed with the SEC on November 7, 2024, a the SEC. These forward-looking statement the date hereof and Vericel does not a disclaims any obligation to update any of statements to reflect a chan ...

Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth of 58% to $53.4 Million Record Fourth Quarter Gross Margin of 78%, Adjusted EBITDA Margin of 40%, and Net Income of $19.8 Million Mid-Term Profitability Targets Increased to Gross Margin in the High-70% Range and Adjusted EBITDA Margin in the High-30% Range Strong MACI Arthro Key Launch Indicators, with Approximately 250 MACI Arthro Surgeons Trained to ...

CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2024 financial results on Thursday, February 27, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of th ...